PPARG and intrahepatic cholangiocarcinoma: PPARG were connected with anal carcinoma (OR = 12.909; 95% CI: 3.217–51.795; P-value = 0.0003), HCC (OR = 36.507; 95% CI: 8.929-149.259; P-value < 0.0001), and ICC (OR = 5.609; 95% CI: 2.772–11.347; P-value < 0.0001), but with lower risks of gastric cancer (OR = 0.691; 95% CI: 0.500-0.956; P-value = 0.026) and pancreatic cancer (OR = 0.110; 95% CI: 0.071–0.172; P-value < 0.0001).